CA2736664C - The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide - Google Patents

The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide Download PDF

Info

Publication number
CA2736664C
CA2736664C CA2736664A CA2736664A CA2736664C CA 2736664 C CA2736664 C CA 2736664C CA 2736664 A CA2736664 A CA 2736664A CA 2736664 A CA2736664 A CA 2736664A CA 2736664 C CA2736664 C CA 2736664C
Authority
CA
Canada
Prior art keywords
compound
mesylate
salt
ptk787
rat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2736664A
Other languages
English (en)
French (fr)
Other versions
CA2736664A1 (en
Inventor
Kaihong Yuan
Piaoyang Sun
Yunshu Zhou
Yongjiang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CA2736664A1 publication Critical patent/CA2736664A1/en
Application granted granted Critical
Publication of CA2736664C publication Critical patent/CA2736664C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA2736664A 2008-09-16 2009-06-11 The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide Active CA2736664C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2008101496511A CN101676267B (zh) 2008-09-16 2008-09-16 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐
CN200810149651.1 2008-09-16
PCT/CN2009/072239 WO2010031266A1 (zh) 2008-09-16 2009-06-11 N-[4-(1-氰基环戊基)苯基]-2-（4-吡啶甲基）氨基-3-吡啶甲酰胺的盐

Publications (2)

Publication Number Publication Date
CA2736664A1 CA2736664A1 (en) 2010-03-25
CA2736664C true CA2736664C (en) 2016-05-24

Family

ID=42029001

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2736664A Active CA2736664C (en) 2008-09-16 2009-06-11 The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide

Country Status (12)

Country Link
US (1) US8362256B2 (enExample)
EP (1) EP2327697B1 (enExample)
JP (1) JP5649132B2 (enExample)
KR (1) KR101674227B1 (enExample)
CN (1) CN101676267B (enExample)
AU (1) AU2009295168B2 (enExample)
BR (1) BRPI0919018A2 (enExample)
CA (1) CA2736664C (enExample)
MX (1) MX2011002816A (enExample)
RU (1) RU2499796C2 (enExample)
WO (1) WO2010031266A1 (enExample)
ZA (1) ZA201101891B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104072412A (zh) * 2014-07-08 2014-10-01 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐b晶型及其制备方法和应用
CN104086484B (zh) * 2014-07-08 2016-05-25 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐溶剂化物晶体及其制备方法和应用
CN104072411A (zh) * 2014-07-08 2014-10-01 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐c晶型及其制备方法和应用
CN104072413A (zh) * 2014-07-08 2014-10-01 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐a晶型及其制备方法和应用
CN104072410B (zh) * 2014-07-08 2017-02-08 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐d晶型及其制备方法和应用
CN104086483A (zh) * 2014-07-08 2014-10-08 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐f晶型及其制备方法和应用
CN105622499A (zh) * 2014-10-28 2016-06-01 华东理工常熟研究院有限公司 硫酸阿帕替尼的新晶型
CN105541708A (zh) * 2014-10-28 2016-05-04 华东理工常熟研究院有限公司 硫酸阿帕替尼的新晶型
CN105622498A (zh) * 2014-10-28 2016-06-01 华东理工常熟研究院有限公司 硫酸阿帕替尼的新晶型
JP6714017B6 (ja) 2015-04-15 2020-07-22 ダウ グローバル テクノロジーズ エルエルシー 垂直方向に伸長された気泡を有する断熱発泡体
CN105801476A (zh) * 2016-04-13 2016-07-27 上海宣创生物科技有限公司 阿帕替尼甲磺酸盐ii晶型及其制备方法和应用
CN106243031B (zh) * 2016-07-26 2017-09-08 江苏恒瑞医药股份有限公司 一种阿帕替尼的制备方法
TWI764943B (zh) 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
TWI771344B (zh) * 2016-12-01 2022-07-21 大陸商江蘇恆瑞醫藥股份有限公司 一種ｖｅｇｆｒ抑制劑與ｐａｒｐ抑制劑聯合在製備治療胃癌的藥物中的用途
CN108250138A (zh) * 2016-12-28 2018-07-06 上海宣创生物科技有限公司 阿帕替尼a晶型及其制备方法和应用
CN106963948A (zh) * 2017-05-12 2017-07-21 顾艳宏 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用
CN109381436A (zh) * 2017-08-14 2019-02-26 江苏恒瑞医药股份有限公司 阿帕替尼药物组合物及其制备方法
CN109394685B (zh) * 2017-08-15 2021-04-06 江苏恒瑞医药股份有限公司 一种vegfr抑制剂的药物组合物及其制备方法
WO2019034048A1 (zh) * 2017-08-15 2019-02-21 江苏恒瑞医药股份有限公司 一种vegfr抑制剂晶型及其制备方法
WO2019094832A1 (en) * 2017-11-10 2019-05-16 Lsk Biopharma A combination therapy with apatinib for the treatment of cancer
BR112020010435A2 (pt) 2017-12-06 2020-11-24 Jiangsu Hengrui Medicine Co., Ltd. uso de inibidor da parp no tratamento de câncer de ovário ou câncer de mama resistente à quimioterapia
CN109942487A (zh) * 2017-12-21 2019-06-28 江苏恒瑞医药股份有限公司 一种吡啶类化合物及其制备方法、用途
TW201929900A (zh) 2017-12-29 2019-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｐｄ－１抗體和阿帕替尼聯合治療三陰性乳腺癌的用途
WO2020051173A1 (en) * 2018-09-05 2020-03-12 Assia Chemical Industries Ltd New crystalline polymorphs of rivoceranib and rivoceranib mesylate
WO2021203769A1 (zh) * 2020-04-10 2021-10-14 江苏恒瑞医药股份有限公司 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
WO2004013102A1 (de) * 2002-07-31 2004-02-12 Schering Aktiengesellschaft Vegfr-2 und vegfr-3 inhibitorische anthranylamidpyrimidene
CN1281590C (zh) * 2002-11-27 2006-10-25 南京凯衡科贸有限公司 具有抑制血管生成活性的六员氨基酰胺类衍生物
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
EP2327697B1 (en) 2014-03-12
BRPI0919018A2 (pt) 2015-12-08
JP5649132B2 (ja) 2015-01-07
EP2327697A4 (en) 2012-06-06
RU2499796C2 (ru) 2013-11-27
MX2011002816A (es) 2011-04-05
US8362256B2 (en) 2013-01-29
ZA201101891B (en) 2012-05-30
RU2011113229A (ru) 2012-10-27
CA2736664A1 (en) 2010-03-25
AU2009295168A1 (en) 2010-03-25
KR101674227B1 (ko) 2016-11-08
HK1141514A1 (en) 2010-11-12
CN101676267A (zh) 2010-03-24
EP2327697A1 (en) 2011-06-01
AU2009295168B2 (en) 2014-02-13
KR20110059877A (ko) 2011-06-07
JP2012502885A (ja) 2012-02-02
CN101676267B (zh) 2012-12-26
WO2010031266A1 (zh) 2010-03-25
US20110184023A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
CA2736664C (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide
JP6503317B2 (ja) Ｃ−ｍｅｔ調節剤の薬学的組成物
CN110582483B (zh) 含邻氨基杂芳环炔基的化合物及其制备方法和用途
JP7319383B2 (ja) マルチターゲットキナーゼ阻害剤、医薬組成物、並びにマルチターゲットキナーゼ阻害剤の製造方法及び適用
WO2024051702A1 (zh) 用作cdk4激酶抑制剂的化合物及其应用
CN101686970A (zh) 邻氨基苯甲酰胺吡啶脲及苯甲酰胺衍生物的协同组合
CA2958741C (en) Quinazoline derivatives
CN102786469A (zh) 邻吡啶酰肼衍生物及其制法和药物组合物与用途
CN109476634B (zh) 喹唑啉衍生物的盐的晶体
CN114630819A (zh) 用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法以及包含其作为活性成分的药物组合物
EA032865B1 (ru) НОВАЯ КРИСТАЛЛИЧЕСКАЯ СОЛЕВАЯ ФОРМА 3-(1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИН-3-ИЛЭТИНИЛ)-4-МЕТИЛ-N-(4-((4-МЕТИЛПИПЕРАЗИН-1-ИЛ)МЕТИЛ)-3-ТРИФТОРМЕТИЛФЕНИЛ)БЕНЗАМИДА ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ
CN104109118B (zh) 邻吡啶酰肼衍生物及其制法和药物组合物与用途
CN104109121B (zh) N′-芳乙酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途
TWI462738B (zh) Ｎ－〔４－（１－氰基環戊基）苯基〕－２－（４－吡啶甲基）胺基－３－吡啶甲醯胺的鹽
CN103570616B (zh) N′‑直链烷酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途
HK1141514B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
CN108299397B (zh) 一种用于降血压的活性药物及其制备方法
TWI515186B (zh) 治療腫瘤疾病的醫藥組成物
HK1157189A1 (en) Pharmaceutical composition for the treatment of tumor diseases
HK1157189B (en) Pharmaceutical composition for the treatment of tumor diseases
HK1142526A (en) Synergistic combination of anthranilamide pyridinureas and benzamide derivatives
HK1218758B (zh) 作为c-met激酶抑制剂的化合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140512

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250521

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250521